Metoprolol Tartrate API

Metoprolol Tartrate API: Complete Manufacturer Guide for India's Most Widely Exported Beta-Blocker API Metoprolol Tartrate API sourcing requires reliable quality, cGMP manufacturing, pharmacopoeial compliance, regulatory documentation, and consistent supply for immediate-release and injectable cardiovascular formulations.

Metoprolol Tartrate remains one of the highest-volume cardiovascular APIs manufactured and exported from India. While its extended-release succinate counterpart has captured the once-daily dosing market for chronic heart failure management, the tartrate salt continues to dominate immediate-release tablet production, injectable formulations, and combination cardiovascular products across semi-regulated and regulated markets worldwide. Pharmaceutical procurement teams sourcing Metoprolol Tartrate API from India in 2026 face a supplier landscape that is technically mature but significantly variable in quality documentation depth, regulatory standing, and manufacturing process consistency.

This guide covers everything a pharmaceutical buyer, regulatory affairs professional, or formulation scientist needs to evaluate before sourcing Metoprolol Tartrate API from an Indian manufacturer: the chemistry that distinguishes the tartrate salt from the succinate form, the pharmacopoeial quality standards that regulated-market buyers must meet, the manufacturing and cGMP controls that predict supply quality, and the regulatory documentation package required for US ANDA and EU MA filings.

Metoprolol Tartrate vs Metoprolol Succinate: Understanding the Salt Difference

Metoprolol Tartrate (CAS 56392-17-7, molecular formula C34H56N2O12, molecular weight 684.8 g/mol) is the tartaric acid salt of metoprolol, a selective beta-1 adrenoceptor antagonist. It differs from Metoprolol Succinate (CAS 9841847-4) in three clinically and pharmaceutically relevant ways: the counter-ion (tartaric acid versus succinic acid), the resulting crystal properties and solubility profile, and the dosage form applications for which each salt is suitable.

Metoprolol Tartrate dissolves rapidly in aqueous media, producing peak plasma metoprolol concentrations within 1.5 to 2 hours after oral administration of an

immediate-release tablet. This pharmacokinetic profile supports twice to fourtimes-daily dosing for conditions where rapid onset is clinically appropriate, including acute hypertensive episodes and perioperative beta-blockade. It is also the standard salt for intravenous metoprolol injectable formulations used in acute myocardial infarction management protocols, a clinical application for which the tartrate salt has decades of established use in hospital formularies worldwide.

From a manufacturing perspective, the tartrate salt synthesis produces a different impurity profile and physical specification compared to the succinate route, with distinct critical process parameters at the salt formation and crystallisation stages.

Buyers evaluating an Indian metoprolol tartrate API manufacturer in India should confirm that the supplier's process chemistry documentation specifically addresses the tartrate salt synthesis, not a shared process description that conflates the two salt forms.

Pharmacopoeial Quality Standards: USP, BP and IP Specifications for Metoprolol Tartrate API

Metoprolol Tartrate API is described in the United States Pharmacopeia, British Pharmacopoeia, European Pharmacopoeia, and Indian Pharmacopoeia. The USP and BP/EP monographs apply different assay limits and impurity thresholds, and buyers sourcing for dual US and EU market supply must confirm that the supplier's process consistently delivers material within the tighter BP/EP range.

Specification Parameter

USP Requirement

BP / EP Requirement

Assay (dried basis)

98.0% to 102.0%

99.0% to 101.0%

Appearance

White or off-white crystalline powder

White crystalline powder

Related Substances (single)

NMT 0.2%

NMT 0.1% (specified)

Water Content (KF)

NMT 0.5%

NMT 0.5%

Residue on Ignition

NMT 0.1%

NMT 0.1%

Optical Rotation (5% w/v)

NLT +14.5 to +16.5 degrees

Complies Ph. Eur. 2.2.7

Heavy Metals

NMT 20 ppm

Complies Ph. Eur. 2.4.8

pH (5% solution)

6.0 to 7.0

Not separately specified

The optical rotation specification is a quality parameter unique to Metoprolol Tartrate relative to the succinate salt, arising from the chiral centre in the tartaric acid counter-ion. L-tartaric acid (the naturally occurring enantiomer) confers a specific optical rotation to the salt. A supplier who sources racemic tartaric acid rather than pure L-tartaric acid will produce a Metoprolol Tartrate batch with a

reduced optical rotation value, potentially failing the pharmacopoeial specification and introducing a product quality question that downstream batch release testing will identify but that could have been prevented through starting material control.

Confirm with any prospective supplier that their tartaric acid source is documented as L-tartaric acid with optical rotation verification as part of the raw material release specification.

Metoprolol Tartrate API Manufacturing: Synthesis Route and cGMP Controls

Metoprolol Tartrate synthesis follows the same metoprolol free base route as the succinate synthesis, para-methoxyphenol epoxidation to the glycidyl ether intermediate, followed by ring-opening aminolysis with isopropylamine, but diverges at the salt formation stage, where L-tartaric acid replaces succinic acid as the counter-ion source. The tartrate salt formation produces a different crystal habit and solubility profile compared to the succinate, and the crystallisation process requires different solvent system composition, temperature profile, and drying conditions to achieve consistent polymorphic form and particle size distribution.

Under ICH Q7, the cGMP framework for API manufacturing, the manufacturer must define and validate the synthesis route from the ICH Q7 starting material through to the final API, with documented critical process parameters (CPPs) at each synthetic step, in-process control (IPC) checkpoints, and batch manufacturing records (BMRs) that capture every parameter for every commercial batch. For Metoprolol Tartrate specifically, the critical process parameters include the molar ratio of metoprolol free base to L-tartaric acid in the salt formation step, the crystallisation temperature and cooling rate, the solvent composition and antisolvent addition profile, and the drying temperature and time endpoint.

The regulatory quality framework that governs cGMP compliance for Metoprolol Tartrate API manufacturing covers not only the synthesis process but also the facility quality systems: data integrity practices, change control, deviation management, vendor qualification, and stability programme design. For buyers who need a detailed explanation of how WHO-GMP, DMF, and CEP certifications intersect with API manufacturing quality systems, the article on WHO-GMP, DMF and CEP compliance for Indian API manufacturers covers the regulatory architecture in full.

Kodel Life: Kodel Life manufactures Metoprolol Tartrate API at 62 MT per month from the Morbi, Gujarat facility under ISO 9001:2015 Quality Management System certification and FDA-compliant cGMP manufacturing practices. The 62 MT per month dedicated capacity reflects the molecule's high global demand volume, with synthesis infrastructure validated for the tartrate salt route specifically. In-process control checkpoints, validated HPLC analytical methods, and Karl Fischer moisture determination are standard at every commercial batch.

Immediate-Release vs Injectable Grade: The Two Primary Applications Oral Immediate-Release Tablets

Metoprolol Tartrate immediate-release tablets are the largest finished-dose application for this API globally. Typical tablet strengths are 25 mg, 50 mg, and 100 mg, with twice-daily dosing for hypertension and angina and up to four-timesdaily dosing in some heart failure protocols where once-daily ER formulations are not indicated. The IR tablet formulation is relatively tolerant of API particle size variation compared to the ER succinate formulation, as the IR release mechanism relies on rapid tablet disintegration and dissolution rather than controlled-rate diffusion. However, content uniformity at low tablet strengths (25 mg) is sensitive to API particle size distribution, and buyers formulating at 25 mg strength should confirm D90 data from their supplier.

Injectable Formulations

Metoprolol Tartrate is the salt used in intravenous metoprolol injectable formulations, typically supplied as a 1 mg/mL or 5 mg/mL solution in single-dose ampoules or vials. Injectable-grade Metoprolol Tartrate API carries additional quality requirements beyond the standard oral tablet grade: endotoxin testing (typically below 0.5 EU/mg or as specified by the finished-dose manufacturer), sterile filtration compatibility confirmation, and in some specifications, a controlled particle size distribution to ensure complete solubilisation at the fill concentration. The pool of Indian Metoprolol Tartrate API manufacturers who can supply injectable-grade material is smaller than the oral-grade supplier pool.

Buyers sourcing for injectable formulations must explicitly confirm these additional specifications during supplier evaluation.

Regulatory Documentation: DMF, EDQM CEP and Export Compliance

The regulatory documentation requirements for Metoprolol Tartrate API sourcing from India follow the same framework as other regulated-market API supply, with the US FDA Drug Master File (Type II DMF) as the primary mechanism for ANDA support and the EDQM Certificate of Suitability (CEP) as the EU MA reference instrument. A Metoprolol Tartrate API manufacturer without an active DMF on the FDA public database cannot support a US ANDA filing. An Indian manufacturer without an EU-GMP certificate from a European competent authority, and either a CEP or adequate Module 3 drug substance documentation, cannot supply EU finished-dose manufacturers who are subject to batch QP release requirements.

For injectable-grade Metoprolol Tartrate API destined for EU sterile manufacturing, additional regulatory considerations apply. The API may be subject to the EU's Good Distribution Practice (GDP) guidelines for distribution of pharmaceutical active substances if it is shipped through an intermediate

distributor. Buyers importing directly from a qualified Indian API manufacturer with a valid EU-GMP certificate may be exempt from GDP broker requirements, but buyers using an intermediate trading company must confirm that the intermediary holds an EU GDP certification for pharmaceutical API. Buyers who are navigating GMP exporter qualification for the first time, particularly for Southeast Asian or Middle Eastern markets where WHO-GMP is the primary certification standard, will find the step-by-step market-by-market documentation framework in the guide to sourcing Metoprolol Succinate API from a GMP exporter in India applicable to Metoprolol Tartrate API export as well, since the HS code, COO, DEA exemption, and destination-authority requirements are consistent across both salt forms.

Stability Programme and Re-Test Period for Metoprolol Tartrate API

Metoprolol Tartrate API has an established re-test period of 24 to 36 months under ICH Q1A recommended storage conditions: at or below 25 degrees Celsius, protected from light and moisture. The API is moderately hygroscopic and should be stored in sealed, moisture-proof packaging; humidity excursions above 75 percent RH can affect moisture content and, in extended exposure, the optical rotation of the salt through partial conversion effects. Long-term stability data at 25 degrees Celsius / 60 percent RH and accelerated data at 40 degrees Celsius / 75 percent RH are required to support the re-test period claim in a regulatory dossier.

Buyers should request stability data summaries from any prospective Metoprolol Tartrate API supplier before committing to a commercial supply arrangement. The stability data must cover the specific pharmacopoeial grade (USP, BP, or IP) the buyer intends to purchase, must be derived from commercial-scale batches rather than laboratory-scale development material, and must include numeric results at each ICH Q1A time point rather than a conclusion-only summary. A re-test period claim of 36 months unsupported by at least 24 months of real-time stability data at the 25 degrees Celsius condition is not a regulatory-grade claim for ANDA or EU MA dossier inclusion.

Key Evaluation Criteria for a Metoprolol Tartrate API Manufacturer 1. GMP Certification Scope and Currency

Verify that the GMP certificate explicitly names the Metoprolol Tartrate API manufacturing line, identifies the issuing authority, and carries an inspection date within the last three years. WHO-GMP covers semi-regulated markets. EU-GMP from a European competent authority is required for EU supply. FDA inspection standing is required for US ANDA support. A certificate that covers only the facility generally, without specifying the product scope, is not adequate for regulatory filings that require evidence of product-line-specific GMP compliance.

2. Active DMF or CEP Status

Verify US DMF status directly on accessdata.fda.gov using the supplier's name or DMF reference number. For EU supply, verify EDQM CEP status on the EDQM public database. A supplier who claims to have a DMF or CEP but cannot provide a verifiable reference number within five business days should be treated as unregistered for regulatory filing purposes until independent verification is complete.

3. Optical Rotation Documentation

Confirm that the supplier tests optical rotation as part of every batch COA and that the raw material release specification for tartaric acid requires L-tartaric acid with optical rotation verification. A supplier who does not document L-tartaric acid optical rotation at the raw material stage is accepting a batch failure risk that will manifest as a finished API optical rotation failure, which will be caught only at COA release, potentially after the batch has been packaged and scheduled for shipment.

4. ICH Q3A Impurity Profile

Request the named impurity profile for the specific tartrate salt synthesis route, including ICH M7 genotoxic impurity assessment for the glycidyl ether epoxide intermediate. A supplier who provides a generic metoprolol impurity profile without differentiating the tartrate-specific impurities from the succinate-specific impurities is not providing route-specific process chemistry documentation.

5. Injectable-Grade Specifications (where applicable)

For injectable-grade sourcing, confirm endotoxin testing method and acceptance criterion, sterile filtration compatibility, and whether the supplier has specific injectable-grade batch records distinct from their oral-grade manufacturing documentation. Injectable-grade API should be manufactured in a dedicated area or at minimum with documented cleaning validation demonstrating bioburden control between oral-grade and injectable-grade batches.

Global Supply from India: Markets, Capacity and Lead Times

India's Metoprolol Tartrate API export infrastructure is well-developed, reflecting the molecule's decades-long position as one of the world's most prescribed cardiovascular drugs. Major Indian API export destinations for Metoprolol Tartrate include the United States, Germany, the United Kingdom, Netherlands, Spain, Thailand, Malaysia, Indonesia, Vietnam, Bangladesh, the United Arab Emirates, Saudi Arabia, Kenya, South Africa, Brazil, and Colombia. The volume of Metoprolol Tartrate API traded globally makes it one of the higher-volume APIs in

the Indian export portfolio, with multiple manufacturers operating commercial synthesis scale.

Buyers who are evaluating both Metoprolol Tartrate and Metoprolol Succinate APIs as part of a cardiovascular API procurement exercise will find the full specification comparison between the tartrate and succinate salts, including the capacity figures, pharmacopoeial grade availability, and regulatory documentation differences between both molecules, covered in the complete guide to Metoprolol Succinate API manufacturing from India.

Kodel Life: Kodel Life's 62 MT per month Metoprolol Tartrate API capacity from the Morbi, Gujarat facility positions the company as one of the higher-volume single-facility tartrate salt producers in India. The dedicated synthesis infrastructure for the tartrate route operates separately from Metoprolol Succinate production, ensuring that the different crystallisation and drying parameters for each salt form do not create cross-contamination risk or scheduling conflicts between the two API product lines.

The Tartrate Salt Remains Foundational to Global Cardiovascular API Supply

Despite the clinical shift toward once-daily Metoprolol Succinate ER therapy for chronic heart failure management, Metoprolol Tartrate API maintains a large and stable global demand base through its position in immediate-release cardiovascular tablets, hospital-use injectable formulations, and combination cardiovascular products. The volume of Metoprolol Tartrate API traded globally, and the number of finished-dose manufacturers who depend on reliable Indian API supply for their cardiovascular generic portfolios, make the supplier selection and qualification decision for this molecule consequential in a way that extends well beyond the perkilogram price comparison.

Kodel Life supplies Metoprolol Tartrate API to IP, BP, USP, and EP pharmacopoeial standards from the Morbi, Gujarat facility, with 62 MT per month production capacity, a complete regulatory documentation package including DMF support and ICH Q1A stability data, and a technical team available for buyer enquiries within one to two business days. Contact info@kodellife.com or call +91 75023 33335 to request a Certificate of Analysis, DMF reference letter, or bulk pricing quotation.